Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $54.00 price target on Immunovant (NASDAQ: IMVT).The analyst commented: 'IMVT reported ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE